AI assistant
STRIDES PHARMA SCIENCE LIMITED — Capital/Financing Update 2024
Jan 11, 2024
62616_rns_2024-01-11_5c8cc4f7-45c0-464d-ae38-f87ef9b9305d.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [145 x 48] intentionally omitted <==
January 11, 2024
BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001
Scrip code: 532531
The National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex Bandra (E) Mumbai - 400 051
Scrip code: STAR
Dear Madam/ Sir,
Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/ HO/ CFD/ CFD-PoD-1/ P/ CIR/ 2023/ 123 dated July 13, 2023
This is to inform you that as part of entity optimization exercise, Fairmed Healthcare AG, Switzerland, a step-down subsidiary of the Company in Switzerland, has entered into a Share Purchase Agreement dated January 9, 2024, for divestment of its 100% shareholding in Eris Pharma GmbH, Germany (Eris) to a third party.
Disclosure under Regulation 30 of SEBI Listing Regulations read with SEBI Circular dated July 13, 2023 relating to the proposed transaction is enclosed.
This is for your information and records.
Thanks & Regards, For Strides Pharma Science Limited, Digitally signed by MANJULA R MANJULA R Date: 2024.01.11 15:13:10 +05'30' Manjula Ramamurthy Company Secretary ICSI Membership No. A30515
==> picture [92 x 89] intentionally omitted <==
Encl. As above
==> picture [480 x 53] intentionally omitted <==
==> picture [145 x 48] intentionally omitted <==
Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with SEBI/ HO/ CFD/ CFD-PoD-1/ P/ CIR/ 2023/ 123 dated July 13, 2023
Divestment of 100% stake in Eris Pharma GmbH, Germany by Fairmed Healthcare AG, Switzerland, a step-down subsidiary of the Company
| # | Particulars | Remarks |
|---|---|---|
| a) | Amount and percentage of Turnover or Revenue or Income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year |
The transaction relates to sale of 100% shareholding held in Eris Pharma GmbH, Germany (Eris) by Fairmed Healthcare AG, Switzerland (Fairmed), a step-down subsidiary of the Company. Eris’ revenue for FY23 was ~Euro 5,062 and had a negative networth. |
| b) | Date on which Agreement for Sale has been entered into |
January 9, 2024 |
| c) | Expected Date of Completion of Sale/ Disposal |
Closing shall take place on or before January 31, 2024 OR any other date as mutually agreed between the parties. |
| d) | Consideration received from such Sale/ Disposal |
Euro 200,000 |
| e) | Brief details of Buyers and Whether any of the Buyers belong to Promoter/ Promoter Group/ Group companies. If yes, details thereof |
Maxmind Pharmaceutical SL having its registered office at Calle Copenhague 12, Oficina 205, Edificio Tifan, Las Rozas de Madrid 28232, Spain. Buyer is not related to any of the Promoter/ Promoter Group/ Group Companies of Strides. |
| f) | Whether transaction would fall within Related Party Transactions? If yes, whether the same is done at “Arms’ length”; |
No |
==> picture [480 x 133] intentionally omitted <==
==> picture [145 x 48] intentionally omitted <==
| g) | Whether sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations |
Not Applicable |
|---|---|---|
| h) | Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/ merger, shall be disclosed by the listed entity with respect to such slump sale. For the purpose of this sub-clause, "slump sale" shall mean the transfer of one or more undertakings, as a result of the sale for a lump sum consideration, without values being assigned to the individual assets and liabilities in such sales. |
Not Applicable |
| i) | Reason for delay in intimation | While the Company had sought certain clarifications from the concerned parties, receipt of such clarification was delayed. Consequently, intimation for this transaction to Stock Exchanges is delayed by one day. |
==> picture [92 x 89] intentionally omitted <==
==> picture [480 x 53] intentionally omitted <==